Recently, the AR degradation-promoting compound, dimethylcurcumin (ASC-J9), has been shown to suppress RCC proliferation through a mechanism involving VEGF and HIF1α, providing experimental evidence for a role of AR and androgen signalling in RCC progression. This evidence concerns the gene HIF1A and renal cell carcinoma.